文献速递药物相互作用

强效CYP3A抑制剂酮康唑对非霍奇金淋巴瘤患者维奈克拉药代动力学的影响

Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
PubMed 文献 · Br J Clin Pharmacol · 2017-01-18

本研究为1期开放标签固定序列试验,纳入12例非霍奇金淋巴瘤患者,评估酮康唑对维奈克拉药代动力学的影响。11例可评估患者中,酮康唑使维奈克拉Cmax增加2.3倍(90%CI 2.0-2.7),AUC∞增加6.4倍(90%CI 4.5-9.2)。结果提示CYP3A在维奈克拉消除中起主要作用,需避免与强/中效CYP3A抑制剂或诱导剂联用。

要点

  • 酮康唑使维奈克拉AUC∞增加6.4倍,Cmax增加2.3倍。
  • CYP3A在维奈克拉消除中起主要作用。
  • 维奈克拉剂量爬坡期应避免联用强/中效CYP3A抑制剂或诱导剂。

核心结论

  • 酮康唑多剂量联用显著增加维奈克拉暴露,强烈提示CYP3A在维奈克拉消除中起主要作用。
  • 建议在维奈克拉剂量爬坡期避免联用强效和中效CYP3A抑制剂或诱导剂。
  • 对于已完成爬坡期的患者,推荐根据联用强效和中效CYP3A抑制剂或诱导剂调整维奈克拉剂量。

研究设计与样本

  • 1期、开放标签、固定序列研究,纳入12例非霍奇金淋巴瘤患者。
  • 患者第1天和第8天口服维奈克拉50 mg单次,第5-11天口服酮康唑400 mg每日一次。
  • 第1天和第8天给药前及给药后96小时内采集血样,11例患者有可评估药代动力学数据并纳入统计分析。

主要发现

  • 与单用维奈克拉50 mg相比,酮康唑使维奈克拉平均Cmax增加2.3倍(90%CI:2.0-2.7)。
  • 酮康唑使维奈克拉AUC∞增加6.4倍(90%CI:4.5-9.2;范围:2-12倍)。

临床怎么用

  • 在慢性淋巴细胞白血病患者维奈克拉剂量爬坡期,应避免联用强效和中效CYP3A抑制剂或诱导剂。
  • 对于已完成爬坡期的患者,联用强效和中效CYP3A抑制剂或诱导剂时需调整维奈克拉剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To examine the effect of a strong cytochrome P450 (CYP) 3A inhibitor, ketoconazole, on the pharmacokinetics, safety and tolerability of venetoclax. METHODS: Twelve patients with non-Hodgkin lymphoma (NHL) were enrolled in this Phase 1, open-label, fixed-sequence study. Patients received a single 50 mg dose of venetoclax orally on Day 1 and Day 8, and a 400 mg once daily dose of ketoconazole on Days 5-11. Blood samples were collected predose and up to 96 h after each venetoclax dose on Day 1 and Day 8. RESULTS: Eleven patients had evaluable pharmacokinetic data and were therefore included in the statistical analyses. Compared to administration of a single 50 mg dose of venetoclax alone, ketoconazole increased the venetoclax mean maximum observed plasma concentration (Cmax ) and area under the plasma concentration-time curve from time 0 to infinity (AUC∞ ) by 2.3-fold (90% confidence interval [CI]: 2.0-2.7) and 6.4-fold (90% CI: 4.5-9.2; range: 2- to 12-fold), respectively. CONCLUSIONS: Coadministration of venetoclax with multiple doses of ketoconazole resulted in a significant increase of venetoclax exposures, strongly suggesting that CYP3A plays a major role in elimination of venetoclax in patients. These results suggest the need to avoid concomitant use with strong and moderate inhibitors or inducers of CYP3A during the venetoclax ramp-up phase in chronic lymphocytic leukaemia (CLL) patients. For patients who have completed the ramp-up phase, a modification in venetoclax dose for use with strong and moderate inhibitors or inducers of CYP3A is recommended.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Agarwal SK, Salem AH, Danilov AV, et al. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol. 2017. PMID: 27859472. doi:10.1111/bcp.13175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。